Phase II Study of Medroxyprogesterone Acetate Plus Tamoxifen in Advanced Endometrial Carcinoma: a Gynecologic Oncology Group Study

Overview

Journal Gynecol Oncol

Date 2004 Jan 31

PMID 14751130

Citations 53

Authors

Charles W Whitney

Virginia L Brunetto

Richard J Zaino

Samuel S Lentz

Joel Sorosky

Deborah K Armstrong

Roger B Lee

Affiliations

Soon will be listed here.

Abstract

Objectives: The objectives of this study were to estimate the clinical response rate and toxicity of daily tamoxifen combined with intermittent weekly medroxyprogesterone acetate (MPA).

Methods: This study reports the results of 61 patients with measurable advanced or recurrent endometrial carcinoma enrolled on this study to be treated with tamoxifen 40 mg p.o. daily plus alternating weekly cycles of MPA 200 mg p.o. daily.

Results: One patient was excluded and two patients did not receive study treatment. The percent of patients responding (6 complete and 13 partial) was 33% (95% confidence interval [CI]: 21-46%) among 58 eligible patients who received therapy. Median progression-free survival (PFS) was 3 months and median overall survival (OS) was 13 months.

Conclusion: The combination of daily tamoxifen and intermittent weekly medroxyprogesterone acetate is an active treatment for advanced or recurrent endometrial carcinoma. Further investigation of this combination is appropriate.

Citing Articles

Non-Negative Matrix Tri-Factorization for Representation Learning in Multi-Omics Datasets with Applications to Drug Repurposing and Selection.

Messa L, Testa C, Carelli S, Rey F, Jacchetti E, Cereda C Int J Mol Sci. 2024; 25(17).

PMID: 39273521 PMC: 11394968. DOI: 10.3390/ijms25179576.

Our current understanding of the biological impact of endometrial cancer mtDNA genome mutations and their potential use as a biomarker.

Khadka P, Young C, Sachidanandam R, Brard L, Young M Front Oncol. 2024; 14:1394699.

PMID: 38993645 PMC: 11236604. DOI: 10.3389/fonc.2024.1394699.

Ocular side effects of anticancer agents used in the treatment of gynecologic cancers.

Crowley F, Broderick S, Francis J, OCearbhaill R, Canestraro J Gynecol Oncol. 2024; 188():147-157.

PMID: 38964252 PMC: 11706341. DOI: 10.1016/j.ygyno.2024.06.003.

Case report: prolonged durable clinical benefit and low toxicity from combination endocrine therapy in a patient with recurrent endometrial carcinoma.

Cheng J, Gaillard S, Beavis A, Rushton T, Fader A Front Oncol. 2023; 13:1249370.

PMID: 38090495 PMC: 10711200. DOI: 10.3389/fonc.2023.1249370.

Evolving treatment paradigms in metastatic or recurrent low-grade endometrial cancer: When is hormonal-based therapy the preferred option?.

Mahdi H, Ray-Coquard I, Lorusso D, Mirza M, Monk B, Slomovitz B Int J Gynecol Cancer. 2023; 33(11):1675-1681.

PMID: 37640446 PMC: 10646884. DOI: 10.1136/ijgc-2023-004454.